达格列净用于有心血管风险的糖尿病肾病患者的药物安全性评估。
A drug safety evaluation of dapagliflozin for diabetic nephropathies in patients with cardiovascular risk.
作者信息
Sood Aayushi, Sawhney Aanchal, Borokhovsky Benjamin, Vyas Apurva V, Gupta Rahul
机构信息
Department of Internal Medicine, The Wright Center for Graduate Medical Education, Scranton, PA, USA.
Department of Internal Medicine, Crozer Chester Medical Center, Upland, PA, USA.
出版信息
Expert Opin Drug Saf. 2025 Mar;24(3):241-250. doi: 10.1080/14740338.2025.2462671. Epub 2025 Feb 12.
INTRODUCTION
Diabetic nephropathy is a significant concern for patients with cardiovascular disease. Dapagliflozin, an SGLT2 inhibitor, has emerged as a promising therapeutic approach to managing diabetic nephropathy and reducing cardiovascular risk.
AREAS COVERED
This review encompasses the research and literature search methodology, including clinical trials and real-world evidence, assessing the safety profile of Dapagliflozin in patients with diabetic nephropathy and cardiovascular risk.
EXPERT OPINION
Dapagliflozin, an SGLT2 inhibitor, has redefined patient-centric care by simultaneously improving glycemic control, cardiovascular health, and renal outcomes in individuals with type 2 diabetes, cardiovascular disease, and nephropathy.
引言
糖尿病肾病是心血管疾病患者的一个重大问题。达格列净，一种钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂，已成为治疗糖尿病肾病和降低心血管风险的一种有前景的治疗方法。
涵盖领域
本综述包括研究和文献检索方法，包括临床试验和真实世界证据，评估达格列净在糖尿病肾病和心血管风险患者中的安全性。
专家观点
达格列净，一种SGLT2抑制剂，通过同时改善2型糖尿病、心血管疾病和肾病患者的血糖控制、心血管健康和肾脏结局，重新定义了以患者为中心的护理。
Zotero 插件